52 related articles for article (PubMed ID: 743386)
1. A comparative study of trazodone serum concentrations in patients with normal or impaired renal function.
Catanese B; Dionisio A; Barillari G; De Martino C
Boll Chim Farm; 1978 Jul; 117(7):424-7. PubMed ID: 743386
[No Abstract] [Full Text] [Related]
2. A study of serum levels of trazodone produced in man following single or repeated oral administrations.
Allori L; Catanese B; Cioli V; Interdonato N
Boll Chim Farm; 1978 Sep; 117(9):530-3. PubMed ID: 752360
[No Abstract] [Full Text] [Related]
3. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder.
Pigott TA; L'Heureux F; Rubenstein CS; Bernstein SE; Hill JL; Murphy DL
J Clin Psychopharmacol; 1992 Jun; 12(3):156-62. PubMed ID: 1629380
[TBL] [Abstract][Full Text] [Related]
4. Plasma concentrations of trazodone and 1-(3-chlorophenyl)piperazine in man after a single oral dose of trazodone.
Caccia S; Fong MH; Garattini S; Zanini MG
J Pharm Pharmacol; 1982 Sep; 34(9):605-6. PubMed ID: 6127393
[No Abstract] [Full Text] [Related]
5. Plasma concentrations of trazodone and m-chlorophenylpiperazine at steady state can be predicted from those after an initial dose of trazodone.
Otani K; Mihara K; Yasui N; Ishida M; Kondo T; Tokinaga N; Ohkubo T; Osanai T; Sugawara K; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 1997 Jan; 21(1):239-44. PubMed ID: 9075270
[TBL] [Abstract][Full Text] [Related]
6. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine.
Ishida M; Otani K; Kaneko S; Ohkubo T; Osanai T; Yasui N; Mihara K; Higuchi H; Sugawara K
Int Clin Psychopharmacol; 1995 Sep; 10(3):143-6. PubMed ID: 8675966
[TBL] [Abstract][Full Text] [Related]
7. [Concentration of cefadroxil in kidney tissue and serum after oral administration in patients with normal and impaired renal function].
Degen J; Ringwelski L; Maier-Lenz H
Arzneimittelforschung; 1983; 33(9):1339-42. PubMed ID: 6685518
[TBL] [Abstract][Full Text] [Related]
8. Determination of trazodone and its metabolite, 1-m-chlorophenyl-piperazine, in human plasma and red blood cell samples by HPLC.
Vatassery GT; Holden LA; Hazel DK; Dysken MW
Clin Biochem; 1997 Mar; 30(2):149-53. PubMed ID: 9127697
[TBL] [Abstract][Full Text] [Related]
9. Proceedings: Trazodone: clinical and biochemical studies II. Blood levels and therapeutic responsiveness.
Putzolu S; Pecknold JC; Baiocchi L
Psychopharmacol Bull; 1976 Jan; 12(1):40-1. PubMed ID: 1108084
[No Abstract] [Full Text] [Related]
10. HPLC analysis of the antidepressant trazodone and its main metabolite m-CPP in human plasma.
Mercolini L; Colliva C; Amore M; Fanali S; Raggi MA
J Pharm Biomed Anal; 2008 Aug; 47(4-5):882-7. PubMed ID: 18400445
[TBL] [Abstract][Full Text] [Related]
11. High throughput and sensitive determination of trazodone and its primary metabolite, m-chlorophenylpiperazine, in human plasma by liquid chromatography-tandem mass spectrometry.
Patel BN; Sharma N; Sanyal M; Shrivastav PS
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Aug; 871(1):44-54. PubMed ID: 18621591
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of therapeutic efficacy and pharmacokinetics of controlled release of trazodone in patients with major depressive disorder].
Monteleone P; Delrio G
Minerva Psichiatr; 1994 Dec; 35(4):231-5. PubMed ID: 7861945
[TBL] [Abstract][Full Text] [Related]
13. A retrospective evaluation of plasma trazodone concentrations and clinical response in a primary care clinic.
Tollefson GD; Saxena S; Luxenberg M; Garvey MJ
Hillside J Clin Psychiatry; 1988; 10(2):183-7. PubMed ID: 3224945
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Lidaprim in cases of impaired renal function.
Hitzenberger G; Korn A; Pichler H; Bonelli J; Magometschnigg D
Int J Clin Pharmacol Biopharm; 1977 Jul; 15(7):310-4. PubMed ID: 892947
[TBL] [Abstract][Full Text] [Related]
15. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
Siu YP; Leung KT; Tong MK; Kwan TH
Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of trazodone: methodology and applications.
Abernethy DR; Greenblatt DJ; Shader RI
Pharmacology; 1984; 28(1):42-6. PubMed ID: 6701185
[TBL] [Abstract][Full Text] [Related]
17. Cimetidine pharmacokinetics after oral administration of cimetidine retard in normal and impaired renal function.
Shaheen RA; Zazgornik J; Kuska J; Kokot F; Schneider J
Int J Clin Pharmacol Ther Toxicol; 1990 Nov; 28(11):480-6. PubMed ID: 2272709
[TBL] [Abstract][Full Text] [Related]
18. Trazodone in the treatment of neurotic depression.
Goldberg HL; Finnerty RJ
J Clin Psychiatry; 1980 Dec; 41(12 Pt 1):430-4. PubMed ID: 7440519
[TBL] [Abstract][Full Text] [Related]
19. Plasma trazodone concentrations in elderly depressed inpatients: cardiac effects and short-term efficacy.
Spar JE
J Clin Psychopharmacol; 1987 Dec; 7(6):406-9. PubMed ID: 3429702
[TBL] [Abstract][Full Text] [Related]
20. Trazodone, a triazolopyridine derivative, in primary depressive disorder.
Feighner JP
J Clin Psychiatry; 1980 Jul; 41(7):250-5. PubMed ID: 6993447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
